Techniker Krankenkasse Tender

Contract notice: open house biologika rabattverträge 2021-27 - peginterferon alfa-2a The health insurers involved pursue the goal of entering into discount agreements with all suitable pharmaceutical companies in accordance with section 130a para. 8 sgb v to close the active ingredient peginterferon alfa-2a. the contract is concluded within the framework of the open-house biologics procedure of the health insurance companies: individual negotiations about the content of the contract are not conducted, uniform conditions apply. the health insurances do not guarantee individual contractual partners any exclusivity. the contract term is a maximum of 24 months starting on 02/01/2022. the contract ends on january 31, 2024 at the latest, regardless of the date of the conclusion of the contract. all further information can be found in the participation and contract documents.You can join this open-house biologics process at any time within the contract period with all pharmaceutical companies who meet the requirements of annex 4 to the contract (self-declaration on approval and the company) and confirm this in electronic form in accordance with section 126a of the german civil code the present announcement does not concern the award of a public contract within the meaning of the procurement law guideline (2014/24 / ec) or the antitrust procurement law. in the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the official gazette of the european union. the process designation "open procedure" used in the context of this announcement text according to number iv.1.1) and the specification of the award criteria according to number ii.2.5) are owed to the specifications of the announcement form and have no further meaning. this, as well as the use of the "ted" medium, is not associated with any submission to public procurement regulations, the validity of which is not prescribed by law or procurement regulations.